The Research Education Core of the Pacific Islands Partnership for Cancer Health Equity (PIPCHE) conducted a systematic review of participant learning. All students from both the University of Guam and the University of Hawai'i who have completed the program were asked two open-ended questions, which were then thematically analyzed. (1) What impact did the training have on your career? (2) What did you learn about cancer health disparities? Findings include themes such as expanding social networks, building professional skills, providing opportunities and funding, inspiring a future career in research, and giving back to the community. The results also indicate that students learned that cancer disparities research was complex and diverse, required cultural sensitivity, different areas of cancer research and education, the importance of mentor and peer relationships. Trainees spoke very favorably about the weekly seminar format. These findings are consistent with studies in other similar programs. The authors recommend future educational outcome research.
Betel quid is a psychoactive drug preparation typically made up of a combination of areca quid, slaked lime, piper betel leaf and tobacco. It is the fourth most commonly consumed drug in the world with global use concentrated in the Asia-Pacific region (Boucher and Mannan, 2002; Warnakulasuriya and Peters, 2002). The International Agency for Research on Cancer has classified betel quid as a Group 1 carcinogen (IARC, 2004; Lin et al., 2006), and its use has been associated with oral and oropharyngeal cancer, oral lesions, oral leukoplakia, submucous fibrosis, gum disease, and cancer of the pharynx and esophagus (IARC, 2004; Oakley et al., 2005; Shah et al., 2002; Warnakulasuriya, 2002). This paper reports on the feasibility of an innovative betel quid cessation program carried on the U.S. territory of Guam, and is the first of its kind. The program is described, along with the challenges encountered during the implementation process.
